CoverMyMeds (McKesson) vs Silna Health
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| CoverMyMeds (McKesson) | Silna Health | |
|---|---|---|
| Pricing model | Free to providers (funded by payers/pharma) · Payers, PBMs, pharma fund the network | Not published · Quote-based |
| Speed to go live | Free self-serve portal; EHR-embedded options exist | Share data files; Silna handles setup |
| Automation model | Data / network utility · medication ePA network and portal | Autonomous agents · AI runs benefit checks and auths |
| Built for | Small practices, Mid-size groups, Enterprise systems, Payers | Small practices, Mid-size groups |
| Security posture | No certifications published | SOC 2 Type II, HIPAA |
| Company maturity | 18 yrs (est. 2008) | 3 yrs (est. 2023) |
| Financial backing | Subsidiary of McKesson | $27M · Series A |
| Named customers | None public | None public |
| Published results | No public numbers | Specific numbers public |
| Documented integrations | 5 listed | None documented |
| Third-party validation | None found | None found |
Bottom line
- Pick CoverMyMeds if you want free electronic prior auth for medications with the broadest payer and pharmacy network.
- Pick Silna if you run a therapy or specialty practice (ABA, PT/OT, behavioral) and want benefit checks and prior auths done for you within weeks of signing.
CoverMyMeds (McKesson)
The largest electronic prior authorization network for medications
- Founded
- 2008
- HQ
- Columbus, OH
- Stage
- Subsidiary of McKesson
- Raised
- n/a
What it does
- Electronic prior authorization for retail and specialty drugs
- Specialty enrollment and hub services (RxLightning)
- Medical benefit PA for oncology and radiology (FastAuth)
- Benefit checks and prescription price transparency
- Patient affordability and copay program delivery
Where it's strong
- Network effects are real: it completed 43 million prior authorizations in the 2025 reverification season and most prescribers already have accounts.
- Free for providers and pharmacies, which makes adoption easy.
- McKesson ownership ties it into specialty distribution and pharma services that competitors cannot match.
What buyers should weigh
- Coverage is payer-dependent and shifting: Independence Blue Cross dropped CoverMyMeds for Surescripts ePA in August 2025, so verify your payer mix routes through it.
- It centers on medication PA; medical benefit and procedure prior auth needs mostly require other tools despite the FastAuth acquisition.
- Its revenue comes from pharma and payers, so provider-side feature priorities can lag.
Integrations
Silna Health
Prior auth and benefits automation for therapy providers
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series A
- Raised
- $27M
What it does
- Automates benefit checks and eligibility verification before visits
- Prepares, submits, and tracks prior authorization requests
- Monitors authorizations and flags expirations and renewals
- Covers 1,000+ payers across all 50 states
- Sits alongside existing EHR and practice management systems
- Built for ABA, PT/OT, speech, psychiatry, and other therapy specialties
Where it's strong
- Purpose-built for therapy and specialty providers like ABA, where prior auth volume is the core operational pain.
- Fast deployment because it sits alongside your stack rather than requiring deep EHR integration.
- Strong reported results: insurance verification cut from 30 minutes to 30 seconds and approvals in hours with a claimed 99.8% success rate.
What buyers should weigh
- Young company (founded 2023) with a short track record and no large publicly named customers.
- Narrow front-end focus: it handles benefits and auth, not claims, denials, or the rest of the revenue cycle.
- The no-integration approach means data lives in a separate staff-facing tool rather than flowing into your EHR automatically.
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.